Spexis AG (XSWX:SPEX) Current Accrued Expense : CHF0.00 Mil (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Spexis AG Current Accrued Expense?

Spexis AG's Current Accrued Expense for the quarter that ended in Jun. 2023 was CHF0.00 Mil.

Spexis AG Current Accrued Expense Historical Data

The historical data trend for Spexis AG's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spexis AG Current Accrued Expense Chart

Spexis AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Current Accrued Expense

Get a 7-Day Free Trial

Spexis AG Semi-Annual Data
	Dec13	Dec14	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Current Accrued Expense	Get a 7-Day Free Trial												-	-	-	-	-

Spexis AG Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Spexis AG Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Spexis AG's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Spexis AG (XSWX:SPEX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (XSWX:SPEX) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

SPEXz:UK

Address

Hegenheimermattweg 125, Allschwil, CHE, CH-4123

Website

https://www.polyphor.com

Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.

Spexis AG (XSWX:SPEX) Headlines

No Headlines